Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis.
By P. Prandoni, A. Lensing, A. Piccioli, E. Bernardi, P. Simioni, B. Girolami, A. Marchiori, Paola Sabbion, M. Prins, F. Noventa and 1 more. Blood, 2002
1,875 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Internal Medicine
View Paper: https://www.semanticscholar.org/paper/a7a7e39dd18a9d78f4e1b79c5ba798c10849957a
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- J. F. Timp
- C. Francis
- S. Braekkan
- H. Versteeg
- S. Cannegieter
- F. Rosendaal
- F. V. D. Meer
- J. Vanderschoot
Citations in the corpus
- Incidence of venous thrombosis in a large cohort of 66 329 cancer patients: results of a record linkage study (2006, background): “For cancer patients, incidences of major bleeding of 4–7.5% in 6 months during treatment with low-molecular-weight heparins or oral anticoagulants have been reported [ 14 ,19].”
- Venous Thromboembolism and Cancer: Risks and Outcomes (2003, background): “4,5 In this review, the epidemiology of thrombosis and cancer is discussed in 6 sections: (1) the incidence of VTE in patients with cancer on and off antineoplastic treatment; (2) the tumors most strongly associated with thrombosis; (3) the association between VTE and occult malignancy; (4) manageme”
- Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients (2008, background): “We examined whether the increase in reported rates of VTE was associated with a similar increase in the use of diagnostic procedures for VTE.”
- Epidemiology of cancer-associated venous thrombosis. (2013, background): “However, such treatment comes with a disadvantage of an increased risk of bleeding, which is especially pronounced in cancer patients.(46,53,54) In a prospective follow-up of 842 DVT patients, Prandoni et al investigated bleeding rates during anticoagulant treatment.”
- Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D). (2018, neutral): “9 Currently receiving cancer treatment§ 142 (70) 140 (69) Chemotherapy 120 (85) 113 (81) Radiotherapy 10 (7) 6 (4) Targeted therapy 22 (15) 21 (15) Endocrine therapy 15 (11) 15 (11) Primary tumor type Bladder 4 (2) 10 (5) Brain 2 (1) 1 (1) Breast 20 (10) 20 (10) Cancer unknown primary 3 (2) 3 (1) Ch”